SCHEMBL6693101

SCHEMBL6693101

O=C(O)C(c1ccccc1)N1C(=O)c2c(Cl)c(Cl)c(Cl)c(Cl)c2C1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.57
ALDH1A1 P00352 2/20 0.44
KDM4E B2RXH2 1/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
XIAP P98170 1/20 0.44
HKDC1 Q2TB90 1/20 0.44
HSD17B10 Q99714 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 2/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA9 Q16790 1/20 0.41
MAPT P10636 3/20 0.41
NR1H2 P55055 3/20 0.41
MAPK1 P28482 1/20 0.40
SAE1 Q9UBE0 1/20 0.40
UBA2 Q9UBT2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6694241 0.79 ALDH1A1 (0.57) KMT2AALDH1A1KDM4EALOX15TSHR
SCHEMBL5866035 0.79 ALDH1A1 (0.57) KMT2AALDH1A1KDM4EALOX15TSHR
SCHEMBL6690737 0.79 ALDH1A1 (0.57) KMT2AALDH1A1KDM4EALOX15TSHR
SCHEMBL6688353 0.79 AADAT (0.60) KMT2AALDH1A1KDM4EALOX15TSHR
SCHEMBL30342198 0.75 TP53 (0.52) KMT2AALDH1A1KDM4EALOX15TSHR
SCHEMBL29005218 0.75 TP53 (0.52) KMT2AALDH1A1KDM4EALOX15TSHR
SCHEMBL2982891 0.73 ALDH1A1 (0.48) KMT2AALDH1A1KDM4EALOX15TSHR
SCHEMBL4957962 0.73 LMNA (0.50) KMT2AALDH1A1KDM4EALOX15TSHR
SCHEMBL2995692 0.72 MAPT (0.41) KMT2AALDH1A1KDM4EALOX15TSHR
SCHEMBL9632134 0.72 LMNA (0.53) KMT2AALDH1A1KDM4EALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1477486-A2 Imides as inhibitors of TNF alpha CELGENE CORPORATION (US) 2004-11-17 EP claimed
EP-1477486-A2 Imides as inhibitors of TNF alpha CELGENE CORPORATION (US) 2004-11-17 EP disclosed
US-6200987-B1 ADMINISTERING AS TUMOR NECROSIS FACTOR INHIBITORS; CACHEXIA, ENDOTOXIN SHOCK; RETROVIRUS VIRICIDES CELGENE CORPORATION 2001-03-13 US disclosed
US-6075041-A TUMOR NECROSIS FACTOR CELGENE CORPORATION (US) 2000-06-13 US disclosed
EP-1004572-A2 Amines as inhibitors of TNF alpha CELGENE CORPORATION (US) 2000-05-31 EP disclosed
EP-1004581-A2 Process for the preparation of thalidomide CELGENE CORPORATION (US) 2000-05-31 EP disclosed
EP-1004580-A2 Imides as inhibitors of TNF alpha CELGENE CORPORATION (US) 2000-05-31 EP disclosed
US-5877200-A Cyclic amides CELGENE CORPORATION (US) 1999-03-02 US disclosed
US-5698579-A INHIBITOR OF TUMOR NECROSIS FACTOR CELGENE CORPORATION (US) 1997-12-16 US disclosed
US-5605914-A INHIBITORS OF TUMOR NECROSIS FACTOR CELGENE CORPORATION (US) 1997-02-25 US disclosed
EP-0706521-A1 NOVEL IMIDES CELGENE CORPORATION (US) 1996-04-17 EP disclosed
WO-1995001348-A2 IMIDES AS INHIBITORS OF TNP ALPHA CELGENE CORPORATION (US) 1995-01-12 WO disclosed